Transfusion-dependent Beta-Thalassemia, TDT, (NCT06291961)
Sponsors:
CorrectSequence Therapeutics Co., Ltd
Sponsors:
CorrectSequence Therapeutics Co., Ltd
IND Enabling
Phase I
Phase II
Phase III
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
CorrectSequence Therapeutics
Company Type: Therapeutic development
Main focus: Using innovative base-editing technology to develop novel therapeutics for severe diseases
Company stage: Clinical
Diseases: β-thalassemia and other haemoglobinopathies, metabolic disease, cardiovascular disease, and other genetic disorders
Genome-editing tool: Five proprietary base editors
Funding stage: Angel
Location: Pudong District, Shanghai, China
Website: https://www.correctsequence.com/index.php?lang=en
Pipeline: https://www.correctsequence.com/product1/product.php?class1=245&lang=en
Partners:
CorrectSequence (CorrectSeq) is a clinical-stage biotechnology company that focuses on the use of novel base editors to treat various severe genetic diseases. The company has developed five proprietary base-editing systems; enhanced Base Editor (eBE), dCpf1 Base Editor (dCpf1-BE), human APOBEC3A Base Editor (hA3A-BE), BEACON, and transformer Base Editor (tBE). CorrectSeq is currently conducting a Phase 1 clinical trial of CS-101 for patients with sickle cell disease.
Tags
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
